[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY25032A1 - Procedimiento para preparar una nueva composicion - Google Patents

Procedimiento para preparar una nueva composicion

Info

Publication number
UY25032A1
UY25032A1 UY25032A UY25032A UY25032A1 UY 25032 A1 UY25032 A1 UY 25032A1 UY 25032 A UY25032 A UY 25032A UY 25032 A UY25032 A UY 25032A UY 25032 A1 UY25032 A1 UY 25032A1
Authority
UY
Uruguay
Prior art keywords
composition
pharmaceutically acceptable
compound
acceptable carrier
preparing
Prior art date
Application number
UY25032A
Other languages
English (en)
Inventor
Jai Patel
Hamish Ross
Robin Price
Jeffrey Roger Granett
Original Assignee
Smithkline Beecham Corp Y Smithkline Beecham P L C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Smithkline Beecham Corp Y Smithkline Beecham P L C filed Critical Smithkline Beecham Corp Y Smithkline Beecham P L C
Publication of UY25032A1 publication Critical patent/UY25032A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención describe un procedimiento para preparar una composición farmacéutica de 5-[4-[2-(N-metil-N-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona (Compuesto (I)) en una forma farmacéuticamente aceptable y un vehículo farmacéuticamente aceptable, cuyo procedimiento comprende: (i) preparar una primera composición caracterizada porque la composición es un concentrado del Compuesto (I) en una forma farmacéuticamente aceptable adaptada para ser diluida a fin de proporcionar una composición para administración oral en dosis unitarias y un primer vehículo farmacéuticamente aceptable; (ii) mezclar la primera composición con un segundo vehículo farmacéuticamente aceptable para proporcionar la composición requerida de Compuesto (I). Se ha indicado que una dosis diaria discreta y particular de Compuesto (I) proporciona un efecto especialmente beneficioso sobre el control glicémico y, por lo tanto, es particularmente útil para el tratamiento de la diabetes mellitus.
UY25032A 1997-06-05 1998-06-04 Procedimiento para preparar una nueva composicion UY25032A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition

Publications (1)

Publication Number Publication Date
UY25032A1 true UY25032A1 (es) 1998-11-26

Family

ID=26311662

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25032A UY25032A1 (es) 1997-06-05 1998-06-04 Procedimiento para preparar una nueva composicion

Country Status (29)

Country Link
EP (1) EP0998284A1 (es)
JP (1) JP2001521553A (es)
KR (1) KR20010013410A (es)
CN (3) CN1112926C (es)
AP (1) AP1214A (es)
AR (2) AR008198A1 (es)
AU (1) AU8215098A (es)
BG (1) BG104048A (es)
BR (1) BR9810405A (es)
CA (2) CA2292629C (es)
CO (1) CO4940400A1 (es)
DZ (1) DZ2510A1 (es)
EA (1) EA002384B1 (es)
GB (1) GB9711683D0 (es)
HU (1) HUP0004070A3 (es)
ID (1) ID24264A (es)
IL (1) IL133074A0 (es)
MX (1) MXPA99011322A (es)
NO (2) NO995938L (es)
NZ (2) NZ523725A (es)
OA (1) OA11306A (es)
PE (1) PE78899A1 (es)
PL (1) PL337201A1 (es)
SK (1) SK164899A3 (es)
TR (2) TR200002790T2 (es)
TW (1) TW570797B (es)
UY (1) UY25032A1 (es)
WO (1) WO1998055122A1 (es)
ZA (2) ZA9811572B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20013800A3 (cs) * 1999-04-23 2002-04-17 Smithkline Beecham Plc Polymorf soli 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]-benzyl]thiazolidin-2,4-dionu s kyselinou maleinovou
DE60004658T2 (de) 1999-04-23 2004-06-24 Smithkline Beecham Plc, Brentford Thiazolidindionderivat und seine verwendung als antidiabetikum
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
DE06252444T8 (de) * 2006-05-09 2009-03-19 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(Methyl-2-pyridinylamino)-ethoxy]-phenyl]-methyl]-2,4-thiazolidindion}-bernsteinsäure, Verfahren zur Herstellung und Zusammensetzungen mit Rosiglitazonmaleat
WO2015008234A1 (en) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds as ror gamma modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
CN1083715C (zh) * 1994-02-10 2002-05-01 史密丝克莱恩比彻姆有限公司 胰岛素敏化物治疗肾病的应用
NZ313874A (en) * 1995-08-10 2000-09-29 Warner Lambert Co Compounds used as medicaments useful in eliminating the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
WO1997018811A1 (en) * 1995-11-17 1997-05-29 Warner-Lambert Company A method of treating myotonic dystrophy
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
CN1230114A (zh) * 1996-07-12 1999-09-29 史密丝克莱恩比彻姆有限公司 Leptine抵抗的新疗法

Also Published As

Publication number Publication date
CA2292629C (en) 2004-01-06
TW570797B (en) 2004-01-11
PE78899A1 (es) 1999-10-22
AR015120A1 (es) 2001-04-18
ZA984826B (en) 1999-08-03
TR200002790T2 (tr) 2001-11-21
WO1998055122A1 (en) 1998-12-10
CN1259050A (zh) 2000-07-05
MXPA99011322A (es) 2004-12-02
GB9711683D0 (en) 1997-08-06
NZ513922A (en) 2001-09-28
NZ523725A (en) 2004-09-24
CA2292629A1 (en) 1998-12-10
EA199901116A1 (ru) 2000-06-26
TR199902963T2 (xx) 2000-02-21
CN1526391A (zh) 2004-09-08
IL133074A0 (en) 2001-03-19
ZA9811572B (en) 1999-07-22
NO995938L (no) 2000-02-02
SK164899A3 (en) 2000-11-07
CN1112926C (zh) 2003-07-02
JP2001521553A (ja) 2001-11-06
CA2333352A1 (en) 1998-12-10
HUP0004070A3 (en) 2002-03-28
NO995938D0 (no) 1999-12-03
AP9901696A0 (en) 1999-12-31
NO20040738L (no) 2000-02-02
BG104048A (bg) 2000-07-31
CN1430959A (zh) 2003-07-23
CO4940400A1 (es) 2000-07-24
EP0998284A1 (en) 2000-05-10
KR20010013410A (ko) 2001-02-26
AR008198A1 (es) 1999-12-29
DZ2510A1 (fr) 2003-01-25
BR9810405A (pt) 2000-08-29
HUP0004070A2 (hu) 2002-02-28
PL337201A1 (en) 2000-08-14
OA11306A (en) 2003-10-22
AP1214A (en) 2003-10-08
ID24264A (id) 2000-07-13
EA002384B1 (ru) 2002-04-25
AU8215098A (en) 1998-12-21

Similar Documents

Publication Publication Date Title
UY25049A1 (es) Composiciones para tratamiento para diabetes mellitus
UY25032A1 (es) Procedimiento para preparar una nueva composicion
AR057970A2 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus y procedimientos para preprar dichas composiciones
AP1545A (en) Hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
TW200640455A (en) Oral dosage form comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione
TW200700063A (en) Oral dosage form comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
BR0114196A (pt) Formas polimórficas de maleato de 5-[4-[2-[n-metil-n-(2-piridil) amino]etóxi]benzil]tiazolidina-2,4-diona e processo para a preparação das mesmas.
MY135973A (en) Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative
AR015894A1 (es) Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona e insulina para la preparacion de un medicamento y composicion farmaceuticaque contiene dichos compuestos
UY25102A1 (es) Nueva composición para el tratamiento de diabetes mellitus
NZ515555A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
PE108199A1 (es) Composicion farmaceutica de tiazolidindiona y sulfonilurea
AP1715A (en) The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione
BR0112981A (pt) Sais tartarato de derivado de tiazolidinadiona
AU2002343052A1 (en) Rosiglitazone edisylates and their use as antidiabetics
BR0111536A (pt) Sal de tiazolidinediona para tratamento de diabetes mellitus
GB0021784D0 (en) Novel pharmaceutical
AP2003002737A0 (en) Tartrate salts of thiazolidinedione derivatives
NZ524933A (en) Sodium salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and pharmaceutical composition thereof
AP1841A (en) A thiazolidinedione derivative and its use as antidiabetic.
BR0112982A (pt) Sal tartarato de derivado de tiazolidinadiona
WO2003099337A3 (en) Inclusion complexes of rosiglitazone
BR0112983A (pt) Sais tartarato de derivado de tiazolidinodiona
NZ510672A (en) Composition comprising 5-[4-[2-(N-Methyl-N-2-Pyridyl)Amino)-Ethoxy]Benzyl]Thiazolidine-2,4-Dione

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20180604